Efficacy of Baricitinib in Patients with Moderate-To-Severe Rheumatoid Arthritis up to 6.5 Years of Treatment: Results of a Long-Term Study
Rheumatology 2024 doi 10.1093/rheumatology/keae012 Epub ahead of print
This pooled analysis of four Phase 3 RCTs investigated the long-term efficacy baricitinib in patients with active RA who were MTX-IR, csDMARD-IR, or bDMARD-IR. They found that baricitinib demonstrated efficacy up to 6.5 years and was well tolerated.
Caporali, et al. pooled the results of RA-BEYOND, RA-BEAM, RA-BUILD and RA-BEACON. They measured efficacy using the proportion of patients who achieved LDA or remission at each time point. Physical function was assessed using the proportion of patients who met or exceeded the population normative value of 0.5 based on HAQ-DI.
Keywords:
